A recent review of trial data by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) led to the conclusion that that CTLA-4, PD-1, and PD-L1 inhibitors are not independently associated with risk of infection [13]. The gene discussed is CTLA4; the disease is infection.